H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe ...
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor ...
AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.
Investor's Business Daily on MSN3h
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis TreatmentAnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
Biolog, Inc., a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, today announced the acquisition of Anaerobe Systems, Inc.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback